CD Antigen Cancer Therapy Market Size to Reach USD 93.13 Billion by 2035 on Multi-Antigen and Bispecific Therapy Growth

According to DataM Intelligence, the global CD antigen cancer therapy market size is estimated at USD 30.80 billion in 2025 and is forecast to reach USD 93.13 billion by 2035, expanding at a modeled CAGR of 11.7% during the 2026-2035 forecast period. This places the CD antigen cancer therapy market among the faster-growing segments of oncology therapeutics, reflecting both the scale of established antigen-directed treatments and the rapid commercial expansion of newer modalities built around the same targets.
The market's growth is increasingly driven by how existing CD antigen targets are being used rather than by the discovery of entirely new ones. CD38-directed therapy has moved from later-line treatment into frontline and even pre-active multiple myeloma settings, while BCMA/CD269 has become a multi-modality target supporting CAR-T therapies, bispecific antibodies, and antibody-drug conjugates within the same disease. CD20 is entering what the market treats as a second commercial cycle, as bispecific T-cell engagers are layered on top of decades-old monoclonal antibody use.
Get More About This Market Research Report: https://www.datamintelligence.com/research-report/cd-antigen-cancer-therapy-market?akash

Recent Developments
• Sarclisa Escena Approval (July 2026): The FDA approved Sarclisa Escena, a subcutaneous anti-CD38 therapy delivered through an on-body delivery system, across several multiple-myeloma indications.
• Tecvayli Plus Darzalex Faspro Approval (March 2026): The FDA approved the combination of Tecvayli and Darzalex Faspro for adults with relapsed/refractory multiple myeloma after at least one prior line of therapy, and converted Tecvayli's original monotherapy indication from accelerated to traditional approval.
• Frontline Darzalex Faspro-VRd Approval (January 2026): The FDA approved Darzalex Faspro in combination with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma in adults ineligible for autologous stem-cell transplantation.

Top Growth Drivers in the Market
• Multi-antigen CAR-T development is advancing, with dual CD19/CD20 constructs now in late-stage testing and triple CD19/CD20/CD22 CAR-T cells in earlier-stage development, both aimed at reducing antigen-negative relapse.
• Antigen combination strategies are emerging directly within treatment regimens, exemplified by the pairing of a BCMA-directed bispecific with a CD38-directed antibody in the same relapsed/refractory multiple myeloma indication.
• Subcutaneous and on-body delivery technology is becoming a differentiator across antigen classes, extending from CD38 therapy to CD20 bispecific antibodies.
• Asia-Pacific remains a significant access gap, carrying a substantial share of global non-Hodgkin lymphoma and multiple myeloma cases while still representing a comparatively smaller share of global therapy revenue.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for Quick Response): https://www.datamintelligence.com/download-sample/cd-antigen-cancer-therapy-market?akash
Market Segmentation
By Product Type
• Monoclonal Antibodies
• CAR-T Cell Therapies
• Bispecific/T-Cell Engagers
• Antibody-Drug Conjugates
• Others
Monoclonal antibodies lead the market by a wide margin, driven largely by CD38-directed treatment, while CAR-T and bispecific/T-cell engagers represent the faster-growing modalities as cellular and T-cell-redirecting therapies expand into earlier treatment lines.
By Target Antigen
• CD38
• CD20
• CD19
• BCMA/CD269
• CD30
• CD79b
• CD22
• CD33
• Others
CD38 is the leading antigen category, supported by large-scale frontline use, while BCMA/CD269 is described as the fastest-growing major target segment as it expands across CAR-T, bispecific, and antibody-drug-conjugate modalities.
By Cancer Type
• Multiple Myeloma
• B-Cell Lymphomas
• Leukemias
• Hodgkin Lymphoma
• Others
Multiple myeloma generates the largest disease-specific share of market revenue, reflecting the combined commercial scale of CD38 and BCMA-directed therapies, while B-cell lymphomas represent the next-largest contributor.
By End User
• Hospitals & Comprehensive Cancer Centers
• Cell-Therapy Centers
• Specialty Hematology Clinics
• Others
The report identifies hospitals and comprehensive cancer centers, cell-therapy centers, and specialty hematology clinics as the primary settings for CD antigen-directed treatment, reflecting the infrastructure required for infusion-based antibody therapy, T-cell-engaging bispecifics, and cellular therapy administration.
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa
North America holds the largest regional share, supported by rapid adoption of CAR-T and bispecific therapies, while Asia-Pacific is identified as the fastest-growing region despite currently holding a smaller share relative to its underlying patient population.

Competitive Landscape
• Johnson & Johnson
• Roche/Genentech
• Bristol Myers Squibb
• Gilead/Kite
• Genmab/AbbVie
Johnson & Johnson: Johnson & Johnson holds the strongest overall commercial position in the market through CD38 and BCMA, with its CD38 franchise generating the largest single share of category revenue and the March 2026 Tecvayli-Darzalex approval giving the company a distinctive two-antigen combination strategy.
Roche/Genentech: Roche/Genentech maintains one of the broadest lymphoma portfolios through CD20 and CD79b, spanning Rituxan/MabThera, Gazyva, Lunsumio, Columvi, and Polivy, with Polivy standing out as a consistently strong-performing CD79b-directed therapy.
Bristol Myers Squibb: Bristol Myers Squibb is an increasingly important cellular-therapy competitor through Breyanzi and Abecma, with Breyanzi representing a substantial and growing share of the company's cell-therapy revenue and obtaining a new marginal-zone-lymphoma indication in December 2025.
Speak to Our Analyst and Get Customization in the Report as per Your Requirements: https://www.datamintelligence.com/customize/cd-antigen-cancer-therapy-market?akash

Regional Analysis
Europe represents the second-largest regional market in the report, behind only North America. Within Europe, Germany is the largest individual country market, followed by the UK and France, with Italy and Spain contributing smaller shares. European growth is supported by wider availability of CD38, CD20-bispecific, and CAR-T therapies, along with regulatory progress such as the June 2026 European approval of subcutaneous Sarclisa administered through an on-body injector.
According to the report, North America is the dominant regional market, while Asia-Pacific is identified as the fastest-growing region, a dynamic the report attributes to the region's substantial share of global lymphoma and multiple myeloma cases relative to its current commercial revenue share.

Conclusion
The global CD antigen cancer therapy market growth is poised for significant expansion over the forecast period. While monoclonal antibodies, led by CD38-directed treatment, continue to generate most of the market revenue, the underlying structure of the market is diversifying quickly as CAR-T, bispecific antibodies, and antibody-drug conjugates expand around the same established antigen targets. BCMA/CD269 stands out as a genuinely multi-modality target, and the move toward directly combining antigen classes, such as pairing a BCMA bispecific with a CD38 antibody, signals a shift from competition between targets toward combination-based treatment strategies.
Multiple myeloma remains the largest disease-specific contributor to market revenue, supported by both CD38 and BCMA therapies, while CD20-directed treatment is entering a renewed growth phase through bispecific antibodies in lymphoma. Johnson & Johnson leads the competitive landscape through its CD38 and BCMA franchises, with Roche/Genentech, Bristol Myers Squibb, Gilead/Kite, and Genmab/AbbVie each holding meaningful positions across CD20, CD19, and BCMA-directed therapies. Regionally, North America retains the largest share of the market, Europe holds a substantial secondary position anchored by Germany, the UK, and France, and Asia-Pacific is expected to grow fastest as access to advanced antigen-directed therapies gradually catches up with the region's underlying disease burden.
Unlock Complete Market Intelligence with the Full Report: https://www.datamintelligence.com/buy-now-page?report=cd-antigen-cancer-therapy-market?akash

Industry Related Reports:
Breast Cancer Therapeutics Market Size
The global breast cancer therapeutics market reached USD 37.75 billion in 2024 and is projected to reach USD 72.05 billion by 2033, growing at a CAGR of 9.4% during 2025-2033.
Get more insights: https://www.datamintelligence.com/research-report/breast-cancer-therapeutics-market

Thyroid Cancer Treatment Market Forecast
The global thyroid cancer treatment market reached USD 1.14 billion in 2024 and is expected to reach USD 2.94 billion by 2033, growing at a CAGR of 11.2% during 2025-2033.
Get more insights: https://www.datamintelligence.com/research-report/thyroid-cancer-treatment-market

Get More Japan Market Insights: https://www.datamintelligence.com/jp-market-research-report?akash

Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About Us :
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.